KDMN - Kadmon posts results from mid-stage chronic graft-versus-host disease trial

Kadmon Holdings (KDMN) announces the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil ((KD025)) for chronic graft-versus-host disease ((cGVHD)).Results from KD025-208, the open-label, Phase 2a clinical trial of belumosudil, which enrolled 54 cGVHD patients who had received one to three prior lines of therapy, showed a pooled Overall Response Rate ((ORR)) of 65% across the three patient cohorts.In addition, 50% of responders experienced a clinically meaningful improvement in symptoms, as measured by at least a 7-point decrease in the Lee cGVHD Symptom Scale score.Belumosudil was well tolerated across all cohorts, with no drug-related serious adverse events and no increased risk of infection observed.Shares were down more than 1% premarket.

For further details see:

Kadmon posts results from mid-stage chronic graft-versus-host disease trial